The University of Washington has divulged antibody-drug conjugates (ADCs) comprising an antibody targeting HER2 (erbB2) linked to monomethyl auristatin E (MMAE) through a linker. They are described as useful for the treatment of cancer.
The University of Michigan has disclosed pyrrolo[1,2-a]-azocine analogues acting as as inhibitor of apoptosis proteins (IAP) inhibitors. As such, they are reported to be potentially useful for the treatment of AIDS, cancer, infections, psoriasis, multiple sclerosis, vascular disorders, inflammatory disorders and autoimmune diseases.
Copper is an essential trace element with critical roles in several biological processes; therefore, its levels are tightly regulated by multiple mechanisms. Researchers from Sun Yat-Sen University (Guangzhou, China) and collaborators recently described the design of a series of novel copper ionophores with varying n-alkyl chain lengths.
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell engager consisting of two nanobody domains targeting HER2 and T-cell receptor (TCR) fused to an Fc region harboring the F234A and L235A mutations to inhibit effector function.
Negio Therapeutics NV has disclosed guanfacine derivatives acting as α2-adrenoceptor agonists. They are reported to be useful for the treatment of cancer.
Nagoya University Graduate School of Medicine (Japan) and collaborating institutions aimed to characterize the heterogeneity of myofibroblastic cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma using the KPC mouse model.
D3 Bio Inc. has obtained IND clearance from the FDA for D3S‑003, enabling initiation of a first‑in‑human phase I trial in patients with advanced solid tumors harboring KRAS G12D mutations.
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead.
Rhythm Biosciences Ltd. launched a new genetype colorectal cancer risk assessment clinical test that incorporates clinical and lifestyle risk factors alongside its established 140-SNP polygenic risk score to identify people at elevated risk of colorectal cancer. The test supports more targeted screening and complements Melbourne-based Rhythm’s Colostat blood-based CRC detection test, which debuted in Australia in December 2025.
Idorsia Pharmaceuticals Ltd. and Shanghai Institute of Materia Medica of The Chinese Academy of Sciences have discovered 1,2,3-triazole derivatives acting as L-amino acid oxidase (IL4I1; LAAO) inhibitors designed for use in the treatment of cancer.
RSS
